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AbstrAct:   Introduction: Gastrointestinal bleeding is a common disease that surgeons encounter in everyday clinical practice. It is most of-
ten easy to diagnose and treat. However, rare causes of bleeding can lead to delayed diagnosis and ineffective treatment. Dys-
fibrinogenemia is a qualitative fibrinogen disorder in which functional fibrinogen level is reduced with normal antigenic level. 
  case report: Herein we present the case of a 59-year-old female with recurrent gastrointestinal bleeds, that turned out to be 
an unusual manifestation of congenital dysfibrinogenemia. Detailed imaging and endoscopic diagnostics revealed portal hy-
pertension with a non-bleeding 1-cm gastrointestinal stromal tumor and multiple angiodysplastic lesions in close proximity.
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AbbreVIAtIoNs
angio-CT – computed tomography of blood vessels 
FFP – fresh frozen plasma 
GIST – gastrointestinal stromal tumor 
Hgb – hemoglobin 
HHT – hereditary hemorrhagic telangiectasia 
PLT – thrombocytes 
WBC – white blood cells
INtrodUctIoN
Fibrinogen is a glycoprotein synthesized and secreted into the blood 
primarily by liver hepatocyte cells. Fibrinogen is the most abundant 
clotting factor, with usual blood concentrations ranging from 1.8 to 
3.5 g/L. It also binds to platelets, supports aggregation, and plays an 
important role in wound healing [1, 2]. Congenital dysfibrinogenemia 
is a rare hereditary disease characterized by normal antigen level but 
lower function level of fibrinogen. Clinical manifestation includes 
bleeding or thrombotic events, or both simultaneously [3]. However, 
in many cases dysfibrinogenemia is asymptomatic or has a non-
specific clinical picture, sometimes patients present anemia secondary 
to recurrent occult gastrointestinal bleeding [4].The aim of this 
study was to present the case of a 59-year-old female with recurrent 
gastrointestinal bleeding caused by dysfibrinogenemia.
cAse PreseNtAtIoN
A 59-year-old female was admitted to the Department of General 
Surgery after an upper gastrointestinal bleeding episode. On admis-
sion she complained of exercise tolerance deterioration, dizziness and 
general malaise lasting few days, without stenocardial complaints or 
bleeding symptoms. The patient’s physical examination was general-
ly unremarkable except for skin pallor. No bleeding on the skin or the 
mucosa was observed, previous teeth extractions, delivery and breast 
biopsy caused non-hemorrhagic complications. Family history, howe-
ver, was remarkable: her father and daughter suffered from lifelong, 
spontaneous nose bleeds (however, this was revealed during further 
investigation). She underwent gastroscopy revealing a small gastric 
ulceration on the top of an intramural tumor and angiodysplastic mu-
cosal lesions in its area. Histopathological tests showed chronic gastri-
tis with the presence of Helicobacter pylori. Computed tomography 
confirmed the presence of gastric tumor with a diameter of 10 mm 
suggestive of gastrointestinal tumor (GIST). A surgical treatment was 
considered suspecting that the tumor may be the cause of the bleeding. 
However, preoperative diagnostics revealed portal hypertension in the 
abdominal angio-CT. Diagnosis was supplemented with colonoscopy 
and capsule endoscopy which were without any pathology. Later she 
was hospitalized several times in the Department of Internal Medici-
ne due to recurrent episodes of severe anemia (every 6–8 weeks) and 
treated with packed red blood cells transfusions. Gastroscopy was also 
repeated several times, revealing the same results, without any active 
or past bleeding. Laboratory testing showed severe anemia (HGB level 
7.3 g/dL), moderate leukopenia (WBC count of 2600/uL) and throm-
bocytopenia (PLT count of 126000/uL). Liver parameters were normal. 
Due to the clinical picture, hematological consultation was ordered. 
The patient was diagnosed with dysfibrinogenemia. Clottable fibri-
nogen concentration estimated with von Clauss method was 1.4 g/L 
(normal range 1.8–3.5 g/L) and fibrinogen antigen level determined 
nephelometrically: 3.8 g/L (normal range 1.8–3.5 g/L). Due to tardive 
clinical symptoms onset and concomitantly diagnosed portal hyper-
tension, acquired dysfibrinogenemia was considered first. However, 
fibrinogen concentration measured in the patient’s daughter was also 
diagnostic for dysfibrinogenemia (1.0 g/L with von Clauss method and 
3.0 g/L with nephelometry), which confirms the congenital character 
of this coagulation disorder. Since the patient was ordered to take tra-
nexamic acid at a dose of 1000 mg three times a day, she suffered from 
only one gastrointestinal bleed that was treated with cryoprecipitate. 
She is now being observed in the hemophilia treatment center with 
the intention to implement prophylaxis with fibrinogen concentrate, if 
clinically indicated. Iron supplementation led to resolution of anemia.
dIscUssIoN
Patients with dysfibrinogenemia have an unpredictable clinical 
phenotype. The majority of them are asymptomatic and diagnosed 
incidentally. Clinical manifestations include venous (or rarely 
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mutations and 400 families have been reported on [1]. Abnormal 
fibrinogen is found in patients with liver diseases characterized 
by increased sialic acid content. In the presented case, portal 
hypertension observed in the abdominal angio-CT was probably 
the result of portal vein thrombosis, secondary to hematological 
disease. However, acquired dysfibrinogenemia may also occur in 
other systemic diseases such as multiple myeloma, autoimmune 
disorders, malignancy, and with administration of some medications 
(glucocorticoids, isotretinoin, and antileukemic agents) [9, 11].
Congenital dysfibrinogenemia requires differentiation with other 
congenital hemorrhagic diatheses, especially with inherited von 
Willebrand disease and hereditary hemorrhagic telangiectasia, also 
known as Rendu-Osler-Weber syndrome. Iron-deficient anemia may 
be the main symptom of all these disease entities. The prevalence 
of angiodysplasia in inherited von Willebrand was 2% and 4.5% for 
types 2 and 3, respectively [12]. In case of HHT gastrointestinal 
telangiectasias are quite frequent (70% of patients) and may lead 
to hemorrhages and anemia [13]. Pharmacological treatment is 
based on tranexamic acid administration and implementation of 
prophylaxis with deficient coagulation factor. New drugs could 
be effective in the treatment of gastrointestinal bleeding due to 
angiodysplasia: Thalidomide, Bevacizumab and Tacrolimus [13, 14]. 
Patients with a bleeding phenotype should be referred to 
a hemophilia treatment center for observation and management. 
In cases of bleeding, fresh frozen plasma (FFP), cryoprecipitate 
or fibrinogen concentrate can be administered, according to their 
availability [15]. In the case of acquired dysfibrinogenemia the 
underlying disease should also be treated.
coNcLUsIoNs
The attendant physician must be alert to rare causes of bleeding, 
especially if the patient has simultaneously other organic reasons 
for bleeding. Recurrent idiopathic gastrointestinal bleeding remains 
a diagnostic challenge to the clinician and a constant threat to 
the patient. Although congenital bleeding disorder is a relatively 
rare cause of gastrointestinal bleeding, it should be ruled out in 
patients with chronic anaemia. Bleeds and surgeries in patients with 
fibrinogen deficiencies and other congenital coagulation defects 
should be managed with deficient clotting factor concentrates, in 
strict cooperation with a hemophilia treatment center.
arterial) thrombosis (approximately 20% of patients) or bleeding, 
occurring during invasive procedures (e.g. tooth extraction) or 
spontaneously, like epistaxis (25% of patients) [5, 6]. The prevalence 
of dysfibrinogenemia is estimated at 1–2 per million, however it is 
difficult to establish because of the large number of asymptomatic 
cases [7]. The diagnosis is suspected from prolonged coagulation 
times, with low fibrinogen measured by functional assay. Normal 
or high antigen levels and low functional activity are typical, 
with the ratio of functionally-detected to immunologically-
detected fibrinogen concentration usually below 0.7 [2]. Partial 
thromboplastin time, activated partial thromboplastin time, 
thrombin time, and reptilase time tests are usually prolonged, 
regardless of history of bleeding or thrombosis [3].
In our patient, the diagnosis of dysfibrinogenemia was made only 
after specialist hematological consultation. A gastric tumor suspected 
of being the site of bleeding and recurrent episodes of anemia as 
a chief complaint complicated the diagnostic process. Initially, our 
patient was qualified for laparoscopic wedge-shaped gastrectomy, 
but unexplained, gastrointestinal bleeds were considered to indicate 
high perioperative risk of uncontrolled hemorrhage. In fact, surgery 
would probably have caused hemorrhage, as the diagnosis of the 
bleeding disorder was not known at that time.
Menorrhagia and easy bruising are the most frequent bleeding 
incidences in patients affected with dysfibrinogenemia. 
Gastrointestinal bleeding has also been reported, although much less 
frequently [5, 8]. Wypasek et al. reported that only 3.7% of patients 
developed gastrointestinal bleeding [8]. Another study presented 
a similar incidence of these – 3.5% [9]. Gastrointestinal bleeding as 
the only symptom of dysfibrinogenemia, like in the presented patient, 
poses diagnostic difficulties, because the main reasons for intestinal 
hemorrhages include detectable organic lesions in the digestive 
tract [4]. In general, in case of suspected gastrointestinal bleeding 
the first step is endoscopic examinations focused on bleeding site 
localization, especially duodenal and gastric ulcers. According to the 
diagnostic algorithm, the following tests are usually performed: two 
gastroscopies and two colonoscopies and capsule endoscopy (until 
the bleeding site is found). If negative, rarer reasons for chronic 
anaemia are searched for, including coagulopathy [10].
Dysfibrinogenemia may either be autosomal-dominantly inherited 
or acquired. Regarding congenital dysfibrinogenemia, more than 100 
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